Studies on the reliability of biomarkers for alcohol use and abuse by Modén, Naama
 Institutionen för Laboratoriemedicin, Klinisk Kemi 
Studies on the reliability of biomarkers for 
alcohol use and abuse 
 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska 
Institutet offentligen försvaras i B64, Karolinska Universitetssjukhuset 
Huddinge 
Onsdagen den 30 januari 2013, kl 09:00 
av 
Naama Kenan Modén 
 
Huvudhandledare:  
Adj. Professor Anders Helander 
Karolinska Institutet 
Institutionen för Laboratoriemedicin 
 
Bihandledare:  
Adj. Professor Olof Beck 
Karolinska Institutet 
Institutionen för Medicin, Solna 
 
Professor Jonas Bergquist 
Uppsala Universitet 
Institutionen för kemi 
Avdelningen för analytisk kemi 
Fakultetsopponent: 
Docent Mikael Hedeland 
Uppsala Universitet 
Institutionen för läkemedelskemi  
 
Betygsnämnd: 
Professor Åsa Emmer 
Kungliga Tekniska Högskolan 
Skolan för kemivetenskap 
Tillämpad fysikalisk kemi 
 
Professor Erik Eliasson 
Karolinska Institutet 
Institutionen för Laboratoriemedicin 
 
Docent Tom Palmstierna 
Karolinska Institutet 
Institutionen för klinisk neurovetenskap 
 
Stockholm 2013 
 
 
  
ABSTRACT 
 
Alcohol is consumed by the vast majority of the population, but prolonged excessive 
drinking is associated with various negative health and social consequences. It is therefore 
important to identify individuals with at-risk alcohol consumption, before it turns into abuse 
or dependence. Early detection of alcohol use and abuse can be done by the use of 
biomarkers such as ethyl glucuronide (EtG), carbohydrate-deficient transferrin (CDT), and 
phosphatidylethanol (PEth) that provide objective information about current consumption. 
However, since misleading test results can have devastating consequences, the use of 
reliable biomarkers is substantial. The aim of this thesis was to evaluate several factors, both 
clinical and analytical, that could generate erroneous test results when testing for alcohol use 
by these biomarkers.  
Measurement of urinary EtG levels was done in 482 samples using different liquid 
chromatography-mass spectrometry procedures. Accurate determination of EtG 
concentrations was done according to specific criteria suggested by international guidelines. 
The sensitivity and specificity were calculated for each of four methods by comparing EtG 
results obtained with a fifth reference method that demonstrated the highest selectivity. 
These results showed that meeting the guideline criteria does not always guarantee correct 
identification, and the likelihood of different analytical methods to provide reliable 
analytical results depends on the reporting limit applied. 
Evaluation of the analytical performance of CDT testing was done by comparing two 
different methods in routine use, capillary electrophoresis (CE) and high-performance liquid 
chromatography (HPLC). Most of the problems encountered by CE could be solved by 
using the HPLC method, and it was therefore advised to have access to a confirmatory 
HPLC analysis, when a high throughput method like CE is employed. 
Evaluation of the clinical performance of CDT in pregnancy was done by measuring serum 
transferrin glycoforms in 171 samples collected from 24 healthy women during and after 
pregnancy. A gradual increase in the CDT (%disialotransferrin) level was observed during 
pregnancy, and in many subjects the level approached the upper limit of the reference 
interval. For use in pregnant women, the cutoff value for CDT used to detect risky drinking 
therefore needs to be raised slightly to minimize the risk for false-positive results.  
The possible interference by transferrin glycation on CDT testing was also evaluated. 
Samples subjected to in vitro glycation and samples collected from diabetic patients were 
tested for CDT by HPLC. No interferences were observed in samples from diabetics, which 
contrasted to the effect seen in vitro by transferrin glycation. The results indicated that CDT, 
and also PEth, are reliable markers to identify risky drinking in diabetic patients.  
Taken together, the results of the present studies have identified and suggested ways to 
overcome a number of analytical and clinical interferences with these alcohol biomarkers, 
and thus helped to improve their routine use. 
